Document:

EX-10.8

 EXHIBIT 10.8 

INTELLECTUAL PROPERTY SECURITY AGREEMENT 

This Intellectual Property Security Agreement (this “IP Agreement”) is made February 18, 2015 by and among Bioject Medical Technologies Inc.
(“Bioject”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the “Grantors”), and Life
Sciences Opportunities Fund II (Institutional), L.P. and Life Sciences Opportunities Fund II, L.P., with offices located at 152 West 57 Street, 19th Floor, New York, New York 10019, c/o Signet
Healthcare Partners (the “Noteholders”). 
 RECITALS 

The Grantors issued three hundred thousand and 00/100 ($300,000) principal amount of secured notes to the Noteholders, on the date hereof (the
“Notes”). The Notes provide that the Notes are secured by all the intellectual property of the Grantors. Accordingly, the Grantors will grant to the Noteholders a security interest in all of Grantors’ right title and interest, whether
presently existing or hereafter acquired in, to and under all of the Collateral (as defined therein). 
 NOW, THEREFORE, for good and
valuable consideration, receipt of which is hereby acknowledged and intending to be legally bound, as collateral security for the prompt and complete payment when due of the Notes, Grantors hereby represent, warrant, covenant and agree as follows:

 1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of
Grantors’ present or future obligations under the Notes, Grantors hereby grants a security interest in all of Grantors’ right, title and interest in, to and under its registered and unregistered Collateral (all of which shall collectively
be called the “Collateral”), including, without limitation, the following: 
  

	 	(a)	All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without
limitation the patents and patent applications set forth on EXHIBIT A attached hereto (collectively, the “Patents”); 

(b) Any trademark and service mark rights, slogans, trade dress, and trade names, trade styles, whether registered or not,
applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantors connected with and symbolized by such trademarks, including without limitation those set forth on
EXHIBIT A attached hereto (collectively, the “Trademarks”); 
 (c) Any and all trade secret
rights, including any rights to unpatented inventions, know-how, operating manuals, license rights and agreements, and confidential information, and any and all intellectual property rights in computer software and computer software products now or
hereafter existing, created, acquired or held; 
 (d) All licenses or other rights to use any of the Patents or Trademarks,
and all license fees and royalties arising from such use to the extent permitted by such license or rights; 
 (e) All
amendments, extensions, renewals and extensions of any of the Trademarks, Patents; and 
 (f) All proceeds and products
of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing. 

2. Covenants and Warranties. Grantors represents, warrants, covenants and agrees as follows: 

(a) Grantors are the sole owners of the Collateral, except for licenses granted by Grantors to their customers in the
ordinary course of business.

  
 1 

 (b) Performance of this IP Agreement does not conflict with or result in a
breach of any material agreement to which Grantors are bound. 
 (c) During the term of this IP Agreement, Grantors will
not transfer or otherwise encumber any interest in the Collateral, except for licenses granted by Grantors in the ordinary course of business or as otherwise permitted in this IP Agreement; 

(d) To their knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged
invalid or unenforceable, in whole or in part, and no claim has been made in writing that any part of the Collateral violates the rights of any third party;

(e) Grantors shall advise Noteholders of any subsequent ownership right of the Grantors in or to any Trademark or Patent
specified in this IP Agreement; 
 (f) Grantors shall (i) protect, defend and maintain the validity and
enforceability of the Trademarks and Patents material to Grantors’ business, (ii) use reasonable commercial efforts to detect infringements of the Trademarks and Patents, and promptly advise Noteholders in writing of material infringements
detected and (iii) not allow any Trademarks and Patents, material to Grantors’ business to be abandoned, forfeited or dedicated to the public without the written consent of the Noteholders, which shall not be unreasonably withheld, unless
Grantors determine that reasonable business practices suggest that abandonment is appropriate. 
 (g) Grantors shall
take such further actions as Noteholders may reasonably request from time to time to perfect or continue the perfection of Noteholders’ interest in the Collateral; 

(h) This IP Agreement creates, and in the case of after acquired Collateral this IP Agreement will create, at the time
Grantors first has rights in such after acquired Collateral and Noteholders have taken all actions required for perfection, in favor of Noteholders, a valid and perfected first priority security interest and collateral assignment in the Collateral
in the United States securing the payment and performance of the obligations evidenced by the Notes; 
 (i) To its
knowledge, except for, and upon, the filing of UCC financing statements, or other notice filings or notations in appropriate filing offices, if necessary to perfect the security interests created hereunder, no authorization, approval or other action
by, and no notice to or filing with, any U.S. governmental authority or U.S. regulatory body is required either (a) for the grant by Grantors of the security interest granted hereby, or for the execution, delivery or performance of this IP
Agreement by Grantors in the U.S. or (b) for the perfection in the United States or the exercise by Noteholders of their rights and remedies thereunder; 

(j) All information heretofore, herein or hereafter supplied to Noteholders by or on behalf of Grantors with respect to
the Collateral is true and correct in all material respects. 
 (k) Grantors shall not enter into any agreement that
would materially impair or conflict with Grantors’ obligations hereunder without Noteholders’ prior written consent, which consent shall not be unreasonably withheld. Except as permitted under the Notes, Grantors shall not permit the
inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantors’ rights and interest in any property included within the definition of the
Collateral acquired under such contracts. 
 4. Noteholders’ Rights. Noteholders shall have the right, but not the
obligation, to take, at Grantors’ sole expense, any actions that Grantors is required under this IP Agreement to take but which Grantors fails to timely take, after fifteen (15) days’ notice to Grantors. Grantors shall reimburse and
indemnify Noteholders for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this section 4. 

  
 2 

 5. Further Assurances; Attorney in Fact. 

(a) On a continuing basis, Grantors will, upon reasonable request by Noteholders, subject to any prior licenses, encumbrances and
restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and
collateral agreements and filings with the United States Patent and Trademarks Office and the Register of Copyrights, and take all such action as may reasonably be requested by Noteholders, to perfect Noteholders’ security interest in all
Patents and Trademarks and otherwise to carry out the intent and purposes of this IP Agreement, or for assuring and confirming to Noteholders the grant or perfection of a security interest in all Collateral, provided that Grantors shall not be
required to register any Collateral that Grantors determines, consistent with reasonable business practice, need not be registered. 

(b) Grantors appoints Noteholders as Grantor’s attorney-in-fact, with full authority in the place and stead of Grantors and in the
name of Grantors, Noteholders or otherwise, from time to time in Noteholders’ discretion, upon Grantor’s failure or inability to do so, to take any action and to execute any instrument which Noteholders may deem reasonably necessary or
advisable to accomplish the purposes of this IP Agreement, including: 
 (i) To modify, in its sole discretion, this IP
Agreement without first obtaining Grantor’s approval of or signature to such modification by amending Exhibit A, as appropriate, to include reference to any right, title or interest in any Patents or Trademarks acquired by Grantors after
the execution hereof or to delete any reference to any right, title or interest in any Patents or Trademarks Works in which Grantors no longer have or claim any right, title or interest; and 

(ii) To file, in its sole discretion, one or more financing or continuation statements and amendments thereto, or other
notice filings or notations in appropriate filing offices, relative to any of the Collateral, without notice to Grantors, with all appropriate jurisdictions, as Noteholders deem appropriate, in order to perfect or protect Noteholders’ interest
in the Collateral. 
 6. Events of Default. The occurrence of an Event of Default under the Notes shall constitute an Event of
Default under this IP Agreement. 
 7. Remedies. Upon the occurrence and during the continuance of an Event of Default,
Noteholders shall have the right to exercise all the remedies of a secured party under the Oregon Uniform Commercial Code, including without limitation the right to require Grantors to assemble the Collateral and any tangible property in which
Noteholders have a security interest and to make it available to Noteholders at a place designated by Noteholders. Noteholders shall have a nonexclusive, royalty free license to use the Patents and Trademarks to the extent reasonably necessary to
permit Noteholders to exercise their rights and remedies upon the occurrence and during the continuance of an Event of Default. Grantors will pay any expenses (including reasonable attorney’s fees) incurred by Noteholders in connection with the
exercise of any of Noteholders’ rights hereunder, including without limitation any expense incurred in disposing of the Collateral in accordance with the terms hereof. All of Noteholders’ rights and remedies with respect to the Collateral
shall be cumulative. 
 8. Indemnity. Grantors agrees to defend, indemnify and hold harmless Noteholders and their officers,
employees, and agents (each an “Indemnified Person”) against: (a) all obligations, demands, claims, and liabilities (collectively, “Claims”) claimed or asserted by any other party in connection with the transactions
contemplated by this IP Agreement, and (b) all losses or expenses in any way suffered, incurred, or paid by Noteholders as a result of or in any way arising out of, following or consequential to transactions between Noteholders and Grantors,
under this IP Agreement (including without limitation, reasonable attorney’s fees and reasonable expenses), except for Claims and/or losses arising from or out of an Indemnified Person’s gross negligence or willful misconduct. 

9. Termination. At such time as Grantors shall completely repay the Notes and any other obligations under the Notes, secured
hereunder, Noteholders shall execute and deliver to Grantors all releases, terminations, and other instruments as may be necessary or proper to release the security interest hereunder. 

  
 3 

 10. Course of Dealing. No course of dealing, nor any failure to exercise, nor any
delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof. 
 11. Amendments. This IP
Agreement may be amended only by a written instrument signed by both parties hereto. 
 12. Counterparts. This IP Agreement may
be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument. 

13. Law and Jurisdiction. This IP Agreement shall be governed by and construed in accordance with the laws of the State of Oregon.
GRANTORS ACCEPT FOR THEMSELF AND IN CONNECTION WITH THEIR PROPERTIES, UNCONDITIONALLY, THE NON-EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE OR OREGON IN ANY ACTION, SUIT, OR PROCEEDING OF ANY KIND,
AGAINST IT WHICH ARISES OUT OF OR BY REASON OF THIS IP AGREEMENT; PROVIDED, HOWEVER, THAT IF FOR ANY REASON NOTEHOLDERS CANNOT AVAIL THEMSELVES OF THE COURTS OF THE STATE OF OREGON, GRANTORS ACCEPTS JURISDICTION OF THE COURTS AND VENUE IN ORANGE
COUNTY, CALIFORNIA. NOTWITHSTANDING THE FOREGOING, THE NOTEHOLDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST THE GRANTORS OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH THE NOTEHOLDERS DEEMS NECESSARY OR
APPROPRIATE IN ORDER TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE THE NOTEHOLDERS’ RIGHTS AGAINST THE GRANTORS OR THEIR PROPERTY. 

GRANTORS AND NOTEHOLDERS EACH HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT
OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS. EACH PARTY RECOGNIZES AND AGREES THAT THE FOREGOING
WAIVER CONSTITUTES A MATERIAL INDUCEMENT FOR IT TO ENTER INTO THIS AGREEMENT. EACH PARTY REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING
CONSULTATION WITH LEGAL COUNSEL. 
 14. Confidentiality. In handling any confidential information, Noteholders shall exercise
the same degree of care that they exercise for their own proprietary information, but disclosure of information may be made: (i) to Noteholders’ subsidiaries or affiliates in connection with their present or prospective business relations
with Grantors; (ii) to prospective transferees or purchasers of any interest in the Notes (provided, however, Noteholders shall use commercially reasonable efforts to obtain such prospective transferee’s or purchaser’s agreement to
the terms of this provision); (iii) as required by law, regulation, subpoena, or other order, (iv) as required in connection with Noteholders’ examination or audit; and (v) as Noteholders considers appropriate in exercising
remedies under this Agreement. Confidential information does not include information that either: (a) is in the public domain or in Noteholders’ possession when disclosed to Noteholders, or becomes part of the public domain after
disclosure to Noteholders through no fault of Noteholders; or (b) is disclosed to Noteholders by a third party, if Noteholders reasonably do not know that the third party is prohibited from disclosing the information. 

  
 4 

			
	Grantors:
	
	Bioject Medical Technologies Inc.
		
	By:		 /s/ Tony K. Chow

	Name:		Tony K. Chow
	Title:		President and Chief Executive Officer
	
	Bioject Inc.
		
	By:		 /s / Tony K. Chow

	Name:		Tony K. Chow
	Title:		President and Chief Executive Officer
	
	Noteholders:
	
	Life Sciences Opportunities Fund II, L.P.
	
	 /s/ James Gale

	By Signet Healthcare Partners, LLC
	James Gale, Managing Director
	
	Life Sciences Opportunities Fund II (Institutional), L.P.
	
	 /s/ James Gale

	By Signet Healthcare Partners, LLC
	James Gale, Managing Director

  
 5 

 Exhibit A 

Bioject Medical Technologies Inc. 

Trademark Schedule 
  

					
	 Description
	  	Registration/
Application
Number	  	Registration/
Application
Date
	 USA Trademarks:
	  		  	
			
	 BIOJECT®
	  	2440716	  	4/3/2001

 Bioject Medical Technologies Inc. 

Patent Schedule 
  

					
	 Description
	  	Registration/
Application
Number	  	Registration/
Application
Date
	 USA Patents:
	  		  	
			
	 Multiple use needle-less hypodermic injection device for individual users
	  	5782802	  	7/21/1998

  
 6 

 Bioject Inc. 

Trademark Schedule 
  

					
	 Description
	  	Registration/
Application
Number	  	Registration/
Application
Date
			
	 BIOJECT & Design
	  	2095147	  	9/9/1997
	 BIOJECT ZETAJET
	  	4220613	  	10/9/2012
	 BIOJECTOR
	  	2095148	  	9/9/1997
	 VITAJET
	  	1838619	  	6/7/1994
			
	 Foreign Trademarks:
	  		  	
			
	 B-2000
	  	3300833	  	12/14/2005
	 BIOJECT
	  	3301088	  	1/14/2007
	 BIOJECT
	  	05925 2003	  	8/9/2009
	 BIOJECT & Design
	  	200508684	  	2/23/2006
	 BIOJECT ZETAJET
	  	9701257	  	8/21/2012
	 BIOJECT ZETAJET
	  	9136094	  	11/8/2010
	 BIOJECT ZETAJET
	  	5477139	  	3/9/2012
	 BIOJECT ZETAJET
	  	1542618	  	10/10/2013
	 BIOJECT ZETAJET
	  	2203135	  	11/19/2012
	 BIOJECT and Design
	  	526097	  	3/30/2000
	 BIOJECT and Design
	  	497123	  	3/9/1999
	 BIOJECT and Design
	  	4172641	  	7/31/1998
	 BIOJECTOR & Design
	  	378650	  	1/25/1991
	 PETJET
	  	4310215	  	2/1/2006
	 VET JET
	  	4310207	  	2/22/2006

  
 7 

 Bioject Inc. 

Patent Schedule 
  

					
	 Description
	  	Registration/
Application
Number	  	Registration/
Application
Date
	 US Patents:
	  		  	
			
	 Disposable Needle-free Injection Apparatus and Method
	  	6,607,510	  	8/19/2003
	 Disposable Needle-Free Injection Apparatus and Method
	  	6,641,554	  	11/4/2003
	 Drug Cartridge Assembly and Method of Manufacture
	  	6,883,222	  	4/26/2005
	 Durable Hypodermic Jet Injector Apparatus and Method
	  	6,752,781	  	6/22/2004
	 Durable Needle-less Jet Injector Apparatus and Method
	  	6,648,850	  	11/18/2003
	 Ergonomic Needle-less Jet Injection Apparatus and Method
	  	6,572,581	  	6/3/2003
	 High Workload Needle-Free Injection System
	  	7,156,823	  	1/2/2007
	 Intradermal Injection System for Injecting DNA-Based Injectables into Humans
	  	6,319,224	  	11/20/2001
	 Intradermal Injection System for Injecting DNA-Based Injectables into Humans
	  	6,752,780	  	6/22/2004
	 Jet Injector Apparatus and Method
	  	6,585,685	  	7/1/2003
	 Medication Vial/Syringe Liquid-Transfer Apparatus
	  	5,893,397	  	4/13/1999
	 Needle-Free Injection Devices and Drug Delivery Systems Therefor
	  	7,744,563	  	6/29/2010
	 Needle-Free Injection System
	  	7,717,874	  	5/18/2010
	 Needle-Free Injection System
	  	6,676,630	  	1/13/2004
	 Needle-Free Injection System
	  	7,238,167	  	7/3/2007
	 Needle-Free Injector and Process for Providing Serial Injections
	  	7,942,845	  	5/17/2011
	 Needle-less Injection System
	  	6,506,177	  	1/14/2003
	 Needleless Syringe with Prefilled Cartridge
	  	6,132,395	  	10/17/2000
	 Needleless Syringe with Prefilled Cartridge
	  	6,383,168	  	5/7/2002
	 NGAS Powered Self-Resetting Needle-Less Hypodermic Jet Injection Apparatus and Method
	  	6,096,002	  	8/1/2000
	 Simplified Disposable Needle-Free Injection Apparatus and Method
	  	6,645,170	  	11/11/2003
	 Single-use Needle-less Hypodermic Jet Injection Apparatus and Method
	  	6,264,629	  	7/24/2001

  
 8 

					
	 Single-Use Needle-Less Hypodermic Jet Injection Apparatus and Method
		6,783,509		8/31/2004
	 Single-use Needle-less Hypodermic Jet Injection Apparatus and Method
		6,689,093		2/10/2004
	 Spring Powered Needle-Free Injection System
		7,442,182		10/28/2008
	 Triggering Mechanism for a Needle-Free Injector
		7,547,293		6/16/2009
	 Needle-Free Injection Device with Nozzle Auto-Disable
		8,617,099		12/31/2013
	 Needle-Free Injection System
		7,854,720		12/29/2010
	 Needleless Syringe with Prefilled Cartridge
		6,383,168		5/7/2002
			
	 Foreign Patents:
				
			
	 Drug Cartridge Assembly and Method of Manufacture
		4816/BE/2011		3/11/2011
	 Drug Cartridge Assembly and Method of Manufacture
		1551476		8/28/2003
	 Drug Cartridge Assembly and Method of Manufacture
		1551476		3/11/2011
	 Intradermal Injection System for Injecting DNA-Based Injectables into Humans
		1,229,950		5/18/2005
	 Intradermal Injection System for Injecting DNA-Based Injectables into Humans
		ZL 00813342.5		11/2/2005
	 Single-use Needle-less Hypodermic Jet Injection Apparatus and Method
		229947		8/12/2005
	 Needle-Free Injection System
		1748811		12/19/2012
	 Needle-Free Injection Device with Nozzle Auto-Disable
		HK1149516		11/1/2013
	 Needle-Free Injection Device with Nozzle Auto-Disable
		ZL 200880118480.4		02/06/13
	 Needle-Free Injection System
		4,633,792		12/02/2010
	 Needle-Free Injection System
		5171893		1/11/2013
	 Needle-Free Injection System
		1748811		12/19/2012

  
 9Exhibit42

Exhibit 4.2

CERTIFICATE AS TO ACTIONS TAKEN BY OFFICER
OF SOUTHERN CALIFORNIA EDISON COMPANY
Adopted January 13, 2015
		
	RE:
	CREATION AND ISSUANCE OF THREE NEW SERIES 
OF FIRST AND REFUNDING MORTGAGE BONDS

WHEREAS, by a resolution adopted on December 12, 2013 entitled “Resolution Re:  Financing Authorizations,” the Board of Directors of this corporation delegated to the undersigned officer the authority to authorize and create an additional bonded indebtedness of this corporation to be represented by three new series of its First and Refunding Mortgage Bonds, Series 2015A (the “Series 2015A Bonds”), Series 2015B (the “Series 2015B Bonds”) and Series 2015C (the “Series 2015C Bonds”) (collectively, the “New Bonds”), and take all other actions necessary to create the New Bonds and cause the New Bonds to be issued, sold, and delivered;
NOW, THEREFORE, BE IT RESOLVED, that pursuant to the resolution and the Trust Indenture dated as of October 1, 1923, between this corporation and The Bank of New York Mellon Trust Company, N.A. (successor to Harris Trust and Savings Bank) and D. G. Donovan (successor to Pacific-Southwest Trust & Savings Bank), as Trustees, as amended and supplemented, including as supplemented or proposed to be supplemented by the One Hundred Thirty-Fourth Supplemental Indenture (the “Supplemental Indenture” and collectively, the “Trust Indenture”), the undersigned officer hereby executes and delivers this certificate and takes the actions set forth herein.
BE IT FURTHER RESOLVED, that the undersigned officer hereby authorizes and creates an authorized bonded indebtedness of this corporation in the initial aggregate principal amount of $1,300,000,000, which shall be an increase of, and in addition to, all presently existing 

authorized bonded indebtedness of this corporation, and which shall be represented by the New Bonds.
BE IT FURTHER RESOLVED, that the President or any Vice President and the Secretary or any Assistant Secretary of this corporation are authorized and directed, pursuant to the provisions of Section 1 of Article Two of the Trust Indenture, to sign and present to The Bank of New York Mellon Trust Company, N.A., as Trustee, a certificate stating that the authorized bonded indebtedness of this corporation has been so increased.
BE IT FURTHER RESOLVED, that each of the Chairman of the Board, the Chief Executive Officer, the President, the Senior Vice President and Chief Financial Officer, the Vice President and Treasurer, or any Assistant Treasurer, or any of them acting alone, is authorized and directed to execute and deliver the Supplemental Indenture, in such form as the officer acting may approve, such approval to be evidenced by the execution thereof, and to cause this corporation to perform all of its obligations under the Supplemental Indenture.
BE IT FURTHER RESOLVED, that, subject to the execution and delivery of the Supplemental Indenture, the Series 2015A Bonds, to be issued under and secured by the Trust Indenture, are hereby created in the initial aggregate principal amount of $550,000,000, and the Series 2015A Bonds are hereby designated as “Amortizing First and Refunding Mortgage Bonds, Series 2015A, Due 2022”; the Series 2015A Bonds shall be dated as of their date of issuance, and shall bear interest from January 16, 2015, at the rate of 1.845% per annum on the outstanding  principal amount thereof, payable semiannually on February 1 and August 1 of each year (each, a “Payment Date”); the principal shall be repaid in fourteen equal installments of $39,285,714.29 on each Payment Date, beginning on August 1, 2015 and subject to reduction upon a partial redemption, with the final principal payment on February 1, 2022; the principal of and premium, if 

2

any, and interest on the Series 2015A Bonds shall be payable at the offices of The Bank of New York Mellon Trust Company, N.A., in Chicago, Illinois, or at such other agency or agencies as may be designated by this corporation; all principal, premium, if any, and interest shall be payable in such coin or currency of the United States of America as at the time of payment shall be legal tender for public and private debts; the Series 2015A Bonds shall be transferable only on the books of this corporation at the places designated above for the payment of the principal of and premium, if any, and interest on the Series 2015A Bonds, or at such other agency or agencies as may be designated by this corporation; the Series 2015A Bonds shall be redeemable, at the option of this corporation, in whole or in part, in the manner set forth in the form of definitive Series 2015A Bonds set forth below; the Series 2015A Bonds shall be issuable only as fully registered bonds, without coupons, in denominations of $1,000 and integral multiples of $1,000 in excess thereof; the definitive Series 2015A Bonds shall be numbered from R-1 upward; and the definitive Series 2015A Bonds, and the Certificate of Authentication to be endorsed upon each of the Series 2015A Bonds, shall be substantially in the following form with such legends thereon and changes therein as may be deemed necessary or appropriate by the officer or officers executing the same, and the blanks therein to be properly filled:

(Form of Definitive Series 2015A Bond)

SOUTHERN CALIFORNIA EDISON COMPANY
Amortizing First and Refunding Mortgage Bonds, Series 2015A, Due 2022

No. ____                                    $_____________

SOUTHERN CALIFORNIA EDISON COMPANY, a corporation organized and existing under and by virtue of the laws of the State of California (hereinafter called the “Company”), for value received, hereby promises to pay to _____________________, the registered owner hereof, the principal sum set forth above in fourteen equal installments of $____________ on August 1 and February 1 of each year (each, a “Payment Date”), subject to reduction upon a partial redemption as set forth below.  The final installment of principal will be paid on February 1, 2022 

3

and in any event will equal the then-outstanding principal balance together with accrued and unpaid interest thereon.  

The Company will pay interest on the outstanding principal amount hereof to the registered owner hereof from January 16, 2015, until said principal sum shall be paid, at the rate of 1.845% per annum, payable semiannually on each Payment Date, beginning August 1, 2015.  Such interest shall be paid to the person in whose name this Bond is registered at the close of business on (1) the business day immediately preceding the Payment Date if this Bond is in book-entry only form, or (2) the 15th calendar day before each Payment Date if this Bond is not in book-entry only form.  The amount of interest payable for any period shall be computed on the basis of a 360-day year consisting of twelve 30-day months.  Any payment of less than the full amount of principal and interest due on a Payment Date will first be applied to pay accrued and unpaid interest and second to pay principal.

The principal of and interest on this Bond are payable at the offices of The Bank of New York Mellon Trust Company, N.A., as Trustee, in Chicago, Illinois, or at such other agency or agencies as may be designated by the Company, in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts.

This Bond is one of a series, designated as “Series 2015A, Due 2022,” of a duly authorized issue of bonds of the Company, known as its “First and Refunding Mortgage Bonds,” issued and to be issued in one or more series under and all equally and ratably secured by a Trust Indenture dated as of October 1, 1923, and indentures supplemental thereto, including the One Hundred Thirty-Fourth Supplemental Indenture, dated as of January 14, 2015, which have been duly executed, acknowledged and delivered by the Company to The Bank of New York Mellon Trust Company, N.A. and D. G. Donovan, or one of their predecessors, as Trustees, to which original indenture and indentures supplemental thereto (collectively, the “Trust Indenture”) reference is hereby made for a description of the property, rights and franchises thereby mortgaged and pledged, the nature and extent of the security thereby created, the rights of the holders of this Bond and of the Trustees in respect of such security, and the terms, restrictions and conditions upon which the bonds are issued and secured.

This Bond may be redeemed, in whole or in part, at the option of the Company, at any time prior to its maturity, after notice given in writing (including by facsimile transmission) to the registered owner hereof at the last address shown on the registry books of the Company, by the Company or The Bank of New York Mellon Trust Company, N.A., as Trustee, at least 30 days, but not more than 60 days, before the date fixed for redemption, at a redemption price equal to the greater of (1) the principal amount redeemed or (2) the sum of the present values of the remaining scheduled payments of principal and interest (excluding any interest accrued from the immediately preceding Payment Date to the date fixed for redemption) on this Bond being redeemed, discounted to the date fixed for redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Yield plus 15 basis points, plus accrued and unpaid interest to the date fixed for redemption. 

4

A partial redemption of this Bond will result in each remaining principal payment being reduced in the same proportion as the aggregate unpaid principal amount of this Bond has been reduced by such partial redemption.

“Treasury Yield” means, for any date fixed for redemption, the rate per year equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for the date fixed for redemption.

“Comparable Treasury Issue” means the United States Treasury security or securities selected by an Independent Investment Banker as having an actual or interpolated maturity comparable to the remaining term to stated maturity of the Series 2015A Bonds to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Series 2015A Bonds to be redeemed.

“Comparable Treasury Price” means, for any date fixed for redemption, the average of four Reference Treasury Dealer Quotations for the date fixed for redemption, after excluding the highest and lowest such Reference Treasury Dealer Quotations.

“Independent Investment Banker” means Citigroup Global Markets Inc. or its successor or, if such firm or its successor, as applicable, is unwilling or unable to select the Comparable Treasury Issue, one of the remaining Reference Treasury Dealers appointed by us.

“Reference Treasury Dealer” means (1) Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc. and UBS Securities LLC or, and any other primary U.S. Government securities dealer in the United States of America (a “Primary Treasury Dealer”) designated by, and not affiliated with, any of the foregoing or their successors, provided, however, that if any of the foregoing, or any of their designees, ceases to be a Primary Treasury Dealer, we will appoint another Primary Treasury Dealer as a substitute, and (2) any other Primary Treasury Dealer selected by us.

“Reference Treasury Dealer Quotations” means, for each Reference Treasury Dealer and any date fixed for redemption, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by the Reference Treasury Dealer at 5:00 p.m. New York City time on the third business day preceding the date fixed for redemption.

If the Company elects to redeem fewer than all the Series 2015A Bonds, The Bank of New York Mellon Trust Company, N.A., as Trustee, will select the particular bonds to be redeemed on a pro rata basis, by lot or by such other method of random selection, if any, that The Bank of New York Mellon Trust Company, N.A., as Trustee, deems fair and appropriate; provided, however, that as long as this Bond is held with a depositary, any such selection shall be in accordance with such depositary’s applicable procedures.

Any notice of redemption, at the Company’s option, may state that the redemption will be conditional upon receipt by the paying agent, on or prior to the date fixed for the redemption, of 

5

money sufficient to pay the principal of and premium, if any, and interest, if any, on the Series 2015A Bonds to be redeemed and that if the money has not been so received, the notice will be of no force and effect and the Company will not be required to redeem this Bond.

The Trust Indenture makes provision for a Special Trust Fund and permits the use of moneys therein for the purpose, among others, of redeeming or purchasing this Bond.

If default shall be made in the payment of any installment of principal of or interest on this Bond or in the performance or observance of any of the covenants and agreements contained in the Trust Indenture, and such default shall continue as provided in the Trust Indenture, then the principal of this Bond may be declared and become due and payable as provided in the Trust Indenture.

This Bond is transferable only on the books of the Company at any of the places designated above for the payment of the principal of and premium, if any, or interest on this Bond, or at such other agency or agencies as may be designated by the Company, by the registered owner or by an attorney of such owner duly authorized in writing, on surrender hereof properly endorsed, and upon such surrender hereof, and the payment of charges, a new registered bond or bonds of this series, of an equal aggregate principal amount, will be issued to the transferee in lieu hereof, as provided in the Trust Indenture.

The terms of the Trust Indenture may be modified as set forth in the Trust Indenture; provided, however, that, among other things, (1) the obligation of the Company to pay the principal of and premium, if any, and interest on all bonds outstanding under the Trust Indenture, as at the time in effect, shall continue unimpaired, (2) no modification shall give any of said bonds any preference over any other of said bonds, and (3) no modification shall authorize the creation of any lien prior to the lien of the Trust Indenture on any of the trust property.

No recourse shall be had for the payment of the principal of and premium, if any, or interest on this Bond, or any part thereof, or for or on account of the consideration herefor, or for any claim based hereon, or otherwise in respect hereof, or of the Trust Indenture, against any past, present or future stockholder, officer or director of the Company or of any predecessor or successor company, whether for amounts unpaid on stock subscriptions, or by virtue of any statue or constitution, or by the enforcement of any assessment or penalty, or because of any representation or inference arising from the capitalization of the Company or of such predecessor or successor company, or otherwise; all such liability being, by the acceptance hereof and as a part of the consideration for the issue hereof, expressly released.

This Bond shall not be valid or obligatory for any purpose until it shall have been authenticated by the execution of the certificate of authentication hereon of The Bank of New York Mellon Trust Company, N.A., as Trustee, or its successor in trust.

6

IN WITNESS WHEREOF, Southern California Edison Company has caused this Bond to be executed in its name by its President or one of its Vice Presidents and its corporate seal to be hereto affixed and attested by its Secretary or one of its Assistant Secretaries, as of January __, 2015, such execution and attestation to be by manual or facsimile signatures.

	
			
	 
	 
	SOUTHERN CALIFORNIA EDISON COMPANY

	ATTEST: ______________________
	 
	By: ___________________________

	[Assistant] Secretary
	 
	[Vice] President

(Form of Certificate of Authentication for all Series 2015A Bonds)

Trustee’s Certificate

This is to certify that this Bond is one of the Bonds, of the series designated therein, described and referred to in the Trust Indenture within mentioned.

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., TRUSTEE

By _________________________________
[Authorized Agent]

(End of Form of Series 2015A Bond)
BE IT FURTHER RESOLVED, that, subject to the execution and delivery of the Supplemental Indenture, the Series 2015B Bonds, to be issued under and secured by the Trust Indenture, are hereby created in the initial aggregate principal amount of $325,000,000, and the Series 2015B Bonds are hereby designated as “First and Refunding Mortgage Bonds, Series 2015B, Due 2022”; the Series 2015B Bonds shall be dated as of their date of issuance, shall mature on February 1, 2022, and shall bear interest from January 16, 2015, at the rate of 2.400% per annum on the principal amount thereof, payable semiannually on each Payment Date; the principal of and premium, if any, and interest on the Series 2015B Bonds shall be payable at the offices of The Bank of New York Mellon Trust Company, N.A., in Chicago, Illinois, or at such other agency 

7

or agencies as may be designated by this corporation; all principal, premium, if any, and interest shall be payable in such coin or currency of the United States of America as at the time of payment shall be legal tender for public and private debts; the Series 2015B Bonds shall be transferable only on the books of this corporation at the places designated above for the payment of the principal of and premium, if any, and interest on the Series 2015B Bonds, or at such other agency or agencies as may be designated by this corporation; the Series 2015B Bonds shall be redeemable, at the option of this corporation, in whole or in part, in the manner set forth in the form of definitive Series 2015B Bond set forth below; the Series 2015B Bonds shall be issuable only as fully registered bonds, without coupons, in denominations of $1,000 and integral multiples of $1,000 in excess thereof; the definitive Series 2015B Bonds shall be numbered from R-1 upward; and the definitive Series 2015B Bonds, and the Certificate of Authentication to be endorsed upon each of the Series 2015B Bonds, shall be substantially in the following form with such legends thereon and changes therein as may be deemed necessary or appropriate by the officer or officers executing the same, and the blanks therein to be properly filled:

(Form of Definitive Series 2015B Bond)

SOUTHERN CALIFORNIA EDISON COMPANY
First and Refunding Mortgage Bonds, Series 2015B, Due 2022

No. ____                                    $_____________

SOUTHERN CALIFORNIA EDISON COMPANY, a corporation organized and existing under and by virtue of the laws of the State of California (hereinafter called the “Company”), for value received, hereby promises to pay to _____________________, the registered owner hereof, the principal sum of $325,000,000 on February 1, 2022, and to pay interest on the unpaid principal amount hereof to the registered owner hereof from January 16, 2015, until said principal sum shall be paid, at the rate of 2.400% per annum, payable semiannually on each Payment Date, beginning August 1, 2015.  Such interest shall be paid to the person in whose name this Bond is registered at the close of business on (1) the business day immediately preceding the Payment Date if this Bond is in book-entry only form, or (2) the 15th calendar day before each Payment Date if this Bond is not in book-entry only form.  The amount of interest payable for any period shall be computed on the basis of a 360-day year consisting of twelve 30-day months.

8

The principal of and interest on this Bond are payable at the offices of The Bank of New York Mellon Trust Company, N.A., as Trustee, in Chicago, Illinois, or at such other agency or agencies as may be designated by the Company, in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts.

This Bond is one of a series, designated as “Series 2015B, Due 2022,” of a duly authorized issue of bonds of the Company, known as its “First and Refunding Mortgage Bonds,” issued and to be issued in one or more series under and all equally and ratably secured by a Trust Indenture dated as of October 1, 1923, and indentures supplemental thereto, including the One Hundred Thirty-Fourth Supplemental Indenture, dated as of January 14, 2015, which have been duly executed, acknowledged and delivered by the Company to The Bank of New York Mellon Trust Company, N.A. and D. G. Donovan, or one of their predecessors, as Trustees, to which original indenture and indentures supplemental thereto (collectively, the “Trust Indenture”) reference is hereby made for a description of the property, rights and franchises thereby mortgaged and pledged, the nature and extent of the security thereby created, the rights of the holders of this Bond and of the Trustees in respect of such security, and the terms, restrictions and conditions upon which the bonds are issued and secured.

This Bond may be redeemed, in whole or in part, at the option of the Company, at any time prior to its maturity, after notice given in writing (including by facsimile transmission) to the registered owner hereof at the last address shown on the registry books of the Company, by the Company or The Bank of New York Mellon Trust Company, N.A., as Trustee, at least 30 days, but not more than 60 days, before the date fixed for redemption, at a redemption price equal to (a) if the date fixed for redemption is before December 1, 2021, the greater of (1) the principal amount redeemed or (2) the sum of the present values of the remaining scheduled payments of principal and interest (excluding any interest accrued from the immediately preceding Payment Date to the date fixed for redemption) on this Bond being redeemed, discounted to the date fixed for redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Yield plus 15 basis points, plus accrued and unpaid interest to the date fixed for redemption and (b) if the date fixed for redemption is on or after December 1, 2021, 100 percent of the principal amount of the Series 2015B Bonds being redeemed plus accrued and unpaid interest thereon to but excluding the date of redemption.

“Treasury Yield” means, for any date fixed for redemption, the rate per year equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for the date fixed for redemption.

“Comparable Treasury Issue” means the United States Treasury security or securities selected by an Independent Investment Banker as having an actual or interpolated maturity comparable to the remaining term to stated maturity of the Series 2015B Bonds to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Series 2015B Bonds to be redeemed.

9

“Comparable Treasury Price” means, for any date fixed for redemption, the average of four Reference Treasury Dealer Quotations for the date fixed for redemption, after excluding the highest and lowest such Reference Treasury Dealer Quotations.

“Independent Investment Banker” means Citigroup Global Markets Inc. or its successor or, if such firm or its successor, as applicable, is unwilling or unable to select the Comparable Treasury Issue, one of the remaining Reference Treasury Dealers appointed by us.

“Reference Treasury Dealer” means (1) Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc. and UBS Securities LLC or, and any other primary U.S. Government securities dealer in the United States of America (a “Primary Treasury Dealer”) designated by, and not affiliated with, any of the foregoing or their successors, provided, however, that if any of the foregoing, or any of their designees, ceases to be a Primary Treasury Dealer, we will appoint another Primary Treasury Dealer as a substitute, and (2) any other Primary Treasury Dealer selected by us.

“Reference Treasury Dealer Quotations” means, for each Reference Treasury Dealer and any date fixed for redemption, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by the Reference Treasury Dealer at 5:00 p.m. New York City time on the third business day preceding the date fixed for redemption.

If the Company elects to redeem fewer than all the Series 2015B Bonds, The Bank of New York Mellon Trust Company, N.A., as Trustee, will select the particular bonds to be redeemed on a pro rata basis, by lot or by such other method of random selection, if any, that The Bank of New York Mellon Trust Company, N.A., as Trustee, deems fair and appropriate; provided, however, that as long as this Bond is held with a depositary, any such selection shall be in accordance with such depositary’s applicable procedures.

Any notice of redemption, at the Company’s option, may state that the redemption will be conditional upon receipt by the paying agent, on or prior to the date fixed for the redemption, of money sufficient to pay the principal of and premium, if any, and interest, if any, on the Series 2015B Bonds to be redeemed and that if the money has not been so received, the notice will be of no force and effect and the Company will not be required to redeem this Bond.

The Trust Indenture makes provision for a Special Trust Fund and permits the use of moneys therein for the purpose, among others, of redeeming or purchasing this Bond.

If default shall be made in the payment of any installment of principal of or interest on this Bond or in the performance or observance of any of the covenants and agreements contained in the Trust Indenture, and such default shall continue as provided in the Trust Indenture, then the principal of this Bond may be declared and become due and payable as provided in the Trust Indenture.

This Bond is transferable only on the books of the Company at any of the places designated above for the payment of the principal of and premium, if any, or interest on this Bond, or at such other agency or agencies as may be designated by the Company, by the registered owner or by an 

10

attorney of such owner duly authorized in writing, on surrender hereof properly endorsed, and upon such surrender hereof, and the payment of charges, a new registered bond or bonds of this series, of an equal aggregate principal amount, will be issued to the transferee in lieu hereof, as provided in the Trust Indenture.

The terms of the Trust Indenture may be modified as set forth in the Trust Indenture; provided, however, that, among other things, (1) the obligation of the Company to pay the principal of and premium, if any, and interest on all bonds outstanding under the Trust Indenture, as at the time in effect, shall continue unimpaired, (2) no modification shall give any of said bonds any preference over any other of said bonds, and (3) no modification shall authorize the creation of any lien prior to the lien of the Trust Indenture on any of the trust property.

No recourse shall be had for the payment of the principal of and premium, if any, or interest on this Bond, or any part thereof, or for or on account of the consideration herefor, or for any claim based hereon, or otherwise in respect hereof, or of the Trust Indenture, against any past, present or future stockholder, officer or director of the Company or of any predecessor or successor company, whether for amounts unpaid on stock subscriptions, or by virtue of any statue or constitution, or by the enforcement of any assessment or penalty, or because of any representation or inference arising from the capitalization of the Company or of such predecessor or successor company, or otherwise; all such liability being, by the acceptance hereof and as a part of the consideration for the issue hereof, expressly released.

This Bond shall not be valid or obligatory for any purpose until it shall have been authenticated by the execution of the certificate of authentication hereon of The Bank of New York Mellon Trust Company, N.A., as Trustee, or its successor in trust.

IN WITNESS WHEREOF, Southern California Edison Company has caused this Bond to be executed in its name by its President or one of its Vice Presidents and its corporate seal to be hereto affixed and attested by its Secretary or one of its Assistant Secretaries, as of January __, 2015, such execution and attestation to be by manual or facsimile signatures.

	
			
	 
	 
	SOUTHERN CALIFORNIA EDISON COMPANY

	ATTEST: ______________________
	 
	By: ___________________________

	[Assistant] Secretary
	 
	[Vice] President

11

(Form of Certificate of Authentication for all Series 2015B Bonds)

Trustee’s Certificate

This is to certify that this Bond is one of the Bonds, of the series designated therein, described and referred to in the Trust Indenture within mentioned.

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., TRUSTEE

By _________________________________
[Authorized Agent]

(End of Form of Series 2015B Bond)

BE IT FURTHER RESOLVED, that, subject to the execution and delivery of the Supplemental Indenture, the Series 2015C Bonds, to be issued under and secured by the Trust Indenture, are hereby created in the initial aggregate principal amount of $425,000,000, and the Series 2015C Bonds are hereby designated as “First and Refunding Mortgage Bonds, Series 2015C, Due 2045”; the Series 2015C Bonds shall be dated as of their date of issuance, shall mature on February 1, 2045, and shall bear interest from January 16, 2015, at the rate of 3.600% per annum on the principal amount thereof, payable semiannually on each Payment Date; the principal of and premium, if any, and interest on the Series 2015C Bonds shall be payable at the offices of The Bank of New York Mellon Trust Company, N.A., in Chicago, Illinois, or at such other agency or agencies as may be designated by this corporation; all principal, premium, if any, and interest shall be payable in such coin or currency of the United States of America as at the time of payment shall be legal tender for public and private debts; the Series 2015C Bonds shall be transferable only on the books of this corporation at the places designated above for the payment of the principal of and premium, if any, and interest on the Series 2015C Bonds, or at such other agency or agencies as may be designated by this corporation; the Series 2015C Bonds shall be redeemable, 

12

at the option of this corporation, in whole or in part, in the manner set forth in the form of definitive Series 2015C Bond set forth below; the Series 2015C Bonds shall be issuable only as fully registered bonds, without coupons, in denominations of $1,000 and integral multiples of $1,000 in excess thereof; the definitive Series 2015C Bonds shall be numbered from R-1 upward; and the definitive Series 2015C Bonds, and the Certificate of Authentication to be endorsed upon each of the Series 2015C Bonds, shall be substantially in the following form with such legends thereon and changes therein as may be deemed necessary or appropriate by the officer or officers executing the same, and the blanks therein to be properly filled:

(Form of Definitive Series 2015C Bond)

SOUTHERN CALIFORNIA EDISON COMPANY
First and Refunding Mortgage Bonds, Series 2015C, Due 2045

No. ____                                    $_____________

SOUTHERN CALIFORNIA EDISON COMPANY, a corporation organized and existing under and by virtue of the laws of the State of California (hereinafter called the “Company”), for value received, hereby promises to pay to _____________________, the registered owner hereof, the principal sum of $425,000,000 on February 1, 2045, and to pay interest on the unpaid principal amount hereof to the registered owner hereof from January 16, 2015, until said principal sum shall be paid, at the rate of 3.600% per annum, payable semiannually on each Payment Date, beginning August 1, 2015.  Such interest shall be paid to the person in whose name this Bond is registered at the close of business on (1) the business day immediately preceding the Payment Date if this Bond is in book-entry only form, or (2) the 15th calendar day before each Payment Date if this Bond is not in book-entry only form.  The amount of interest payable for any period shall be computed on the basis of a 360-day year consisting of twelve 30-day months.

The principal of and interest on this Bond are payable at the offices of The Bank of New York Mellon Trust Company, N.A., as Trustee, in Chicago, Illinois, or at such other agency or agencies as may be designated by the Company, in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts.

This Bond is one of a series, designated as “Series 2015C, Due 2045,” of a duly authorized issue of bonds of the Company, known as its “First and Refunding Mortgage Bonds,” issued and to be issued in one or more series under and all equally and ratably secured by a Trust Indenture dated as of October 1, 1923, and indentures supplemental thereto, including the One Hundred Thirty-Fourth Supplemental Indenture, dated as of January 14, 2015, which have been duly executed, acknowledged and delivered by the Company to The Bank of New York Mellon Trust 

13

Company, N.A. and D. G. Donovan, or one of their predecessors, as Trustees, to which original indenture and indentures supplemental thereto (collectively, the “Trust Indenture”) reference is hereby made for a description of the property, rights and franchises thereby mortgaged and pledged, the nature and extent of the security thereby created, the rights of the holders of this Bond and of the Trustees in respect of such security, and the terms, restrictions and conditions upon which the bonds are issued and secured.

This Bond may be redeemed, in whole or in part, at the option of the Company, at any time prior to its maturity, after notice given in writing (including by facsimile transmission) to the registered owner hereof at the last address shown on the registry books of the Company, by the Company or The Bank of New York Mellon Trust Company, N.A., as Trustee, at least 30 days, but not more than 60 days, before the date fixed for redemption, at a redemption price equal to (a) if the date fixed for redemption is before August 1, 2044, the greater of (1) the principal amount redeemed or (2) the sum of the present values of the remaining scheduled payments of principal and interest (excluding any interest accrued from the immediately preceding Payment Date to the date fixed for redemption) on this Bond being redeemed, discounted to the date fixed for redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Yield plus 20 basis points, plus accrued and unpaid interest to the date fixed for redemption and (b) if the date fixed for redemption is on or after August 1, 2044, 100 percent of the principal amount of the Series 2015C Bonds being redeemed plus accrued and unpaid interest thereon to but excluding the date of redemption.

“Treasury Yield” means, for any date fixed for redemption, the rate per year equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for the date fixed for redemption.

“Comparable Treasury Issue” means the United States Treasury security or securities selected by an Independent Investment Banker as having an actual or interpolated maturity comparable to the remaining term to stated maturity of the Series 2015C Bonds to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Series 2015C Bonds to be redeemed.

“Comparable Treasury Price” means, for any date fixed for redemption, the average of four Reference Treasury Dealer Quotations for the date fixed for redemption, after excluding the highest and lowest such Reference Treasury Dealer Quotations.

“Independent Investment Banker” means Citigroup Global Markets Inc. or its successor or, if such firm or its successor, as applicable, is unwilling or unable to select the Comparable Treasury Issue, one of the remaining Reference Treasury Dealers appointed by us.

“Reference Treasury Dealer” means (1) Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc. and UBS Securities LLC or, and any other primary U.S. Government securities dealer in the United States of America (a “Primary Treasury Dealer”) designated by, and not affiliated with, any of the foregoing or their successors, provided, however, that if any of the foregoing, or any of their designees, ceases to be a Primary Treasury Dealer, we 

14

will appoint another Primary Treasury Dealer as a substitute, and (2) any other Primary Treasury Dealer selected by us.

“Reference Treasury Dealer Quotations” means, for each Reference Treasury Dealer and any date fixed for redemption, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by the Reference Treasury Dealer at 5:00 p.m. New York City time on the third business day preceding the date fixed for redemption.

If the Company elects to redeem fewer than all the Series 2015C Bonds, The Bank of New York Mellon Trust Company, N.A., as Trustee, will select the particular bonds to be redeemed on a pro rata basis, by lot or by such other method of random selection, if any, that The Bank of New York Mellon Trust Company, N.A., as Trustee, deems fair and appropriate; provided, however, that as long as this Bond is held with a depositary, any such selection shall be in accordance with such depositary’s applicable procedures.

Any notice of redemption, at the Company’s option, may state that the redemption will be conditional upon receipt by the paying agent, on or prior to the date fixed for the redemption, of money sufficient to pay the principal of and premium, if any, and interest, if any, on the Series 2015C Bonds to be redeemed and that if the money has not been so received, the notice will be of no force and effect and the Company will not be required to redeem this Bond.

The Trust Indenture makes provision for a Special Trust Fund and permits the use of moneys therein for the purpose, among others, of redeeming or purchasing this Bond.

If default shall be made in the payment of any installment of principal of or interest on this Bond or in the performance or observance of any of the covenants and agreements contained in the Trust Indenture, and such default shall continue as provided in the Trust Indenture, then the principal of this Bond may be declared and become due and payable as provided in the Trust Indenture.

This Bond is transferable only on the books of the Company at any of the places designated above for the payment of the principal of and premium, if any, or interest on this Bond, or at such other agency or agencies as may be designated by the Company, by the registered owner or by an attorney of such owner duly authorized in writing, on surrender hereof properly endorsed, and upon such surrender hereof, and the payment of charges, a new registered bond or bonds of this series, of an equal aggregate principal amount, will be issued to the transferee in lieu hereof, as provided in the Trust Indenture.

The terms of the Trust Indenture may be modified as set forth in the Trust Indenture; provided, however, that, among other things, (1) the obligation of the Company to pay the principal of and premium, if any, and interest on all bonds outstanding under the Trust Indenture, as at the time in effect, shall continue unimpaired, (2) no modification shall give any of said bonds any preference over any other of said bonds, and (3) no modification shall authorize the creation of any lien prior to the lien of the Trust Indenture on any of the trust property.

15

No recourse shall be had for the payment of the principal of and premium, if any, or interest on this Bond, or any part thereof, or for or on account of the consideration herefor, or for any claim based hereon, or otherwise in respect hereof, or of the Trust Indenture, against any past, present or future stockholder, officer or director of the Company or of any predecessor or successor company, whether for amounts unpaid on stock subscriptions, or by virtue of any statue or constitution, or by the enforcement of any assessment or penalty, or because of any representation or inference arising from the capitalization of the Company or of such predecessor or successor company, or otherwise; all such liability being, by the acceptance hereof and as a part of the consideration for the issue hereof, expressly released.

This Bond shall not be valid or obligatory for any purpose until it shall have been authenticated by the execution of the certificate of authentication hereon of The Bank of New York Mellon Trust Company, N.A., as Trustee, or its successor in trust.

IN WITNESS WHEREOF, Southern California Edison Company has caused this Bond to be executed in its name by its President or one of its Vice Presidents and its corporate seal to be hereto affixed and attested by its Secretary or one of its Assistant Secretaries, as of January __, 2015, such execution and attestation to be by manual or facsimile signatures.

	
			
	 
	 
	SOUTHERN CALIFORNIA EDISON COMPANY

	ATTEST: ______________________
	 
	By: ___________________________

	[Assistant] Secretary
	 
	[Vice] President

(Form of Certificate of Authentication for all Series 2015C Bonds)

Trustee’s Certificate

This is to certify that this Bond is one of the Bonds, of the series designated therein, described and referred to in the Trust Indenture within mentioned.

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., TRUSTEE

By _________________________________
[Authorized Agent]

(End of Form of Series 2015C Bond)

BE IT FURTHER RESOLVED, that New Bonds need not be issued at the same time and such series may be reopened at any time, without notice to, or the consent of, any then-

16

existing holder or holders of any New Bonds, for issuances of additional New Bonds in an unlimited principal amount; and any such additional New Bonds will have the same interest rate, maturity and other terms as those initially issued, except for payment of interest accruing prior to the original issue date of such additional New Bonds and, if applicable, for the first Payment Date following such original issue date.
BE IT FURTHER RESOLVED, that pursuant to the Trust Indenture, as in effect following due execution and delivery of the Supplemental Indenture, the President or any Vice President and the Secretary or any Assistant Secretary of this corporation are authorized and directed, for and in the name and on behalf of this corporation and under its corporate seal (which seal may be either impressed, printed, lithographed or engraved thereon), to execute (which execution may be by a facsimile signature) and to deliver the New Bonds to The Bank of New York Mellon Trust Company, N.A., as Trustee, for authentication in temporary and/or definitive form, and in such aggregate principal amount up to $1,300,000,000 as the President or any Vice President and the Secretary or any Assistant Secretary of this corporation shall in their absolute discretion determine.
BE IT FURTHER RESOLVED, that the President or any Vice President and the Secretary or any Assistant Secretary of this corporation are authorized and directed for and in the name and on behalf of this corporation and under its corporate seal, to execute and to deliver to The Bank of New York Mellon Trust Company, N.A., as Trustee, the written order of this corporation for the authentication and delivery of the New Bonds pursuant to such sections of Article Two of the Trust Indenture as the officers acting may determine.
BE IT FURTHER RESOLVED, that the Secretary or any Assistant Secretary of this corporation is hereby authorized and directed to deliver to, and file with, The Bank of New York 

17

Mellon Trust Company, N.A., as Trustee, a copy of the this certificate of actions taken, certified by the Secretary or any Assistant Secretary of this corporation.
IN WITNESS WHEREOF, the undersigned has executed this certificate as of the date first written above.

/s/ George T. Tabata
__________________________________
George T. Tabata
Assistant Treasurer 
Southern California Edison Company

18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]